Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

Marie Skłodowska-Curie Action · Running

SECRET Exploring the therapeutic potential of perinatal cell SECRETomes

Coordinator
Universita Cattolica Del Sacro Cuore, Italy
Runs
1 September 2024 to 31 August 2028
Status
Running
EU funding
€2.6m
Total cost
—
Partners
11 organisations in 6 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101168752

What the project is doing

In the project's own words, from its summary on CORDIS.

Over the past two decades, cells isolated from human perinatal (or birth-associated) tissues (amniotic membrane, umbilical cord tissue and cells from amniotic fluid), have been shown to provide tremendous pro-regenerative activities. Amongst others, the application of these cells or of components of their secretome, including extracellular vesicles (EVs), have been found to improve myocardial infarction (MI), ischemic stroke (IS) and multiple sclerosis (MS) symptoms in various animal models.

Currently, cell-free therapies represent a frontier for innovation in regenerative medicine for clinical unmet needs, however, very few scientists are trained for their clinical translation. “Exploring the therapeutic potential of perinatal cell SECRETomes - SECRET” sets out with the ambition to train 10 doctoral candidates (DCs) to disentangle the inherent therapeutic potential of perinatal cell secretomes (either as a whole or as fractionated small EVs) in order to possibile translate novel biologics into the clinic.

Their specific focus will be the characterisation, the delivery and the preclinical evaluation of these perinatal secretomes as an innovative therapeutic approaches for MI, IS and MS. To achieve this goal, Università Cattolica del Sacro Cuore (Prof. Ornella Parolini, Italy) unites internationally-renowned academic and non-academic institutions from Italy, The Netherlands, Germany, Belgium, Portugal and Switzerland, to deliver an inter-disciplinary programme that goes beyond current state-of-the-art research in next generation medicinal product development and validation.

These include the development and use of iPSC-derived organoids and organ-on-a-chip models to identify the most efficient perinatal cell secretome in terms of immunomodulation, angiogenesis, anti-fibrotic, cardio-protective and neuro-trophic properties, as well as the assessment of their in vivo cardiac reparative and neuro-regenerative potential using novel delivery methods.

Topics

Who is involved

OrganisationCityCountryRole
Universita Cattolica Del Sacro CuoreMilanoItalyCoordinator
Universiteit AntwerpenAntwerpenBelgiumParticipant
Ente Ospedaliero CantonaleBellinzonaSwitzerlandAssociatedpartner
Universitaetsklinikum EssenEssenGermanyParticipant
Fondazione PoliambulanzaBresciaItalyAssociatedpartner
Innovation Acta SRLSienaItalyAssociatedpartner
Universita Degli Studi Di GenovaGenovaItalyParticipant
Universita Degli Studi Gabriele D'annunzio Di Chieti-PescaraChietiItalyAssociatedpartner
Mimetas BVLeidenNetherlandsParticipant
Stichting Amsterdam UmcAmsterdamNetherlandsAssociatedpartner
Universidade Do MinhoBragaPortugalParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI